Penumbra

The Lightning Flash system. [Image courtesy of Penumbra]Penumbra (NYSE:PEN) today announced the first patient enrolled in STORM-PE, a trial of its Lightning Flash thrombectomy system.

Lightning Flash, a mechanical thrombectomy system, received FDA clearance in January. The system features Penumbra’s novel Lightning intelligent aspiration technology with dual-clot detection algorithms. Combining it with innovative catheter engineering, Penumbra designed Lightning Flash to quickly remove large blood clots, including venous thrombus and pulmonary emboli (PE).

This combination can differentiate between clot and blood. Its design, which helps reduce blood loss and the need for clot-dissolving drugs, may lower the risk of bleeding complications.

The trial evaluates anticoagulation alone against anticoagulation plus Lightning Flash for the treatment of PE. STORM-PE, a first-of-its-kind, multi-center, randomized controlled trial, aims to advance the understan…

Penumbra (NYSE:PEN) this week posted fourth-quarter results that beat the overall consensus on Wall Street.

The Alameda, California-based company — maker of interventional devices for vascular and neuro therapies — reported profits of $3.9 million, or 10¢ per share, on sales of $221.2 million, for the three months ended Dec. 31, 2022. Sales were up 8.43% compared with Q4 2021. Penumbra reported $24.6 million in losses a year ago.

Adjusted to exclude one-time items, earnings per share were 16¢, 1¢ ahead of The Street, where analysts were looking for sales of $217.03 million.

“Our journey to develop the most optimal solution for safe, effective, fast and powerful removal of blood clot wherever it resides in the body is nearly two decades in the making. And the early results from the use of Lightning Flash in venous and PE patients and Thunderbolt in our stroke trial is giving us even more confidence that the computer-orchestrated aspiration is changi…

The REAL y-Series full-body, non-tethered immersive healthcare offering for rehabilitation. [Image from Penumbra]Penumbra (NYSE:PEN) announced today that it launched a full-body, non-tethered immersive healthcare offering for rehabilitation.

Alameda, California–based Penumbra designed its REAL y-Series product with lower and upper body sensors. They allow clinicians to track full-body movement and progress in real-time.

By expanding its virtual reality-based immersive healthcare platform, Penumbra plans to support a broad range of patients. According to a news release, these patients undergoing physical or occupational therapy could improve their physical, cognitive and mental well-being.

“Two of the largest challenges in rehabilitation are maintaining patient motivation and lack of engagement,” said Gita Barry, EVP and GM of Penumbra’s Immersive Healthcare business. “Penumbra’s latest REAL y-series is the only hands-free, sensor-based VR platform available…

[Image from Penumbra]Penumbra (NYSE:PEN) announced today that it received CE mark for its RED reperfusion catheter and began its European launch.

Alameda, California-based Penumbra designed its RED reperfusion catheter for the removal of all clot types in acute ischemic stroke (AIS) patients. Recent data presented by the company demonstrated successful revascularization using the RED system.

Get the full story at our sister site, Medical Tubing & Extrusion.

[Image from Penumbra]Penumbra (NYSE:PEN) announced today that initial data support the use of its RED reperfusion catheters and the Penumbra System.

Alameda, California-based Penumbra presented results from the initial Insight Registry for the RED reperfusion catheters and the sub-analyses of the Complete study study for the Penumbra system at the 2022 World Federation of Interventional and Therapeutic Neuroradiology (WFITN) in Kyoto, Japan.

Get the full story at our sister site, Medical Tubing & Extrusion.

Penumbra (NYSE:PEN) this week posted fourth-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates.

The Alameda, California-based company reported losses of -$24.6 million, or -66¢ per share, on sales of $204 million for the three months ended Dec. 31, 2021, for a sales growth of 22.24% compared with Q4 2020.

Get the full story on our sister site, Medical Tubing + Extrusion.

Penumbra (NYSE:PEN) announced today that the Cheetah clinical study for its Indigo CAT RX catheter met its primary endpoint.

Alameda, California-based Penumbra’s Indigo catheter system demonstrated high rates of blood clot removal, blood flow restoration and myocardial perfusion in conjunction with percutaneous coronary intervention (PCI) in patients with high thrombus burden.

The company presented the results of the Cheetah study at the 2021 Transcatheter Cardiovascular Therapeutics (TCT) conference in Orlando, according to a news release.

Penumbra’s Cheetah study enrolled 400 patients with high thrombus burden who were treated with continuous mechanical aspiration thrombectomy with CAT RX prior to PCI. The trial observed 99.5% of patients experience TIMI thrombus grade 0 after CAT RX and PCI.

Additionally, 97.5% of patients had thrombolysis in myocardial infarction (TIMI) flow grade 3 after CAT RX and PCI, with TIMI increasing signif…